CN112154144A - 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 - Google Patents

一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 Download PDF

Info

Publication number
CN112154144A
CN112154144A CN201980033424.9A CN201980033424A CN112154144A CN 112154144 A CN112154144 A CN 112154144A CN 201980033424 A CN201980033424 A CN 201980033424A CN 112154144 A CN112154144 A CN 112154144A
Authority
CN
China
Prior art keywords
crystal form
formula
compound
peak
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980033424.9A
Other languages
English (en)
Other versions
CN112154144B (zh
Inventor
徐超
邵启云
冯君
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112154144A publication Critical patent/CN112154144A/zh
Application granted granted Critical
Publication of CN112154144B publication Critical patent/CN112154144B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及一种1,2,4‑三嗪‑3‑胺类衍生物的晶型及制备方法。具体地，涉及式(1)化合物的A、B、C、D、E、F、G、H、J晶型及制备方法。式(1)化合物的晶型具备良好的晶型稳定性，可更好地用于临床。(I)

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201980033424.9A 2018-07-13 2019-07-12 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 Active CN112154144B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810767419 2018-07-13
CN2018107674198 2018-07-13
PCT/CN2019/095724 WO2020011245A1 (zh) 2018-07-13 2019-07-12 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法

Publications (2)

Publication Number Publication Date
CN112154144A true CN112154144A (zh) 2020-12-29
CN112154144B CN112154144B (zh) 2022-05-27

Family

ID=69142090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033424.9A Active CN112154144B (zh) 2018-07-13 2019-07-12 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法

Country Status (3)

Country Link
CN (1) CN112154144B (zh)
TW (1) TWI728404B (zh)
WO (1) WO2020011245A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114527042A (zh) * 2021-12-24 2022-05-24 湖南醇健制药科技有限公司 一种黄体酮软胶囊内容物中黄体酮的粒度分布的检测方法
WO2024109937A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物的可药用盐、晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
US20080064653A1 (en) * 2006-06-19 2008-03-13 University Of Virginia Patent Foundation Use of adenosine a2a modulators to treat spinal cord injury
CN102822150A (zh) * 2010-02-05 2012-12-12 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物
CN102892761A (zh) * 2010-03-31 2013-01-23 帕罗生物制药有限公司 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827422A (zh) * 2017-01-13 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 １，２，４－三嗪－３－胺類衍生物、其製備方法及其在醫藥上的應用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
US20080064653A1 (en) * 2006-06-19 2008-03-13 University Of Virginia Patent Foundation Use of adenosine a2a modulators to treat spinal cord injury
CN102822150A (zh) * 2010-02-05 2012-12-12 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物
CN102892761A (zh) * 2010-03-31 2013-01-23 帕罗生物制药有限公司 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114527042A (zh) * 2021-12-24 2022-05-24 湖南醇健制药科技有限公司 一种黄体酮软胶囊内容物中黄体酮的粒度分布的检测方法
WO2024109937A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
TWI728404B (zh) 2021-05-21
WO2020011245A1 (zh) 2020-01-16
TW202019898A (zh) 2020-06-01
CN112154144B (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
US20210017163A1 (en) Hydrochloride salt form for ezh2 inhibition
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
CN112154144B (zh) 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
WO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
WO2015096640A1 (zh) 含噻唑基雷帕霉素类衍生物及其应用
WO2022017494A1 (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
JP7464613B2 (ja) ジアリールチオヒダントイン化合物結晶
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
WO2022206937A1 (zh) 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN115667241B (zh) TrkA抑制剂
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
JP7329052B2 (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
CN112334473B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
WO2023138647A1 (zh) 一种含硫异吲哚啉类衍生物的晶型
BR112019025158A2 (pt) Derivados de ácido carboxílico como inibidores das proteínas quinase
US20220235054A1 (en) Novel maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
CN110386939B (zh) Parp抑制剂的溶剂合物晶体及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant